SER · Serina Therapeutics, Inc.

“Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences" Featuring Serina Therapeutics’ CEO - Wednesday, February 4, 2026 Hear how FDA initiatives in 2026 may impact drug development timelines, review processes, and investor expectations across the life sciences sector Meet with Serina ’s CEO Steven Ledger Register at New-FDA-Era.TribePublic.com HUNTSVILLE, AL, Feb. 03, 2026 (GLOBE NEWSWIRE) - Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, is pleased to announce that Serina’s CEO, Steven Ledger will present at Tribe Public’s Webinar Presentation and Q&A Event titled “Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences". The Event is scheduled to begin at 8:30 am pacific / 11:30 am eastern on Wednesday, February 4, 2026. To register to join the complimentary event, please visit the Tribe

HUNTSVILLE, Jan. 15, 2026 (GLOBE NEWSWIRE) - Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform TM drug optimization technology, received a notice from the New York Stock Exchange ("NYSE") that it is below the continued listing criteria under Sections 1003(a)(i) and (ii) of the NYSE's listing standards set forth in Part 10 of the NYSE American Company Guide ("Company Guide"), because the Company reported stockholders' equity of $1.6 million as of September 30, 2025, and has had losses in three of its four most recent fiscal years ended December 31, 2024. The Company is also not currently eligible for any exemption in Section 1003(a) of the Company Guide from the stockholders' equity requirements. In connection with its non-compliance with Sections 1003(a)(i) and (ii) of the

CINCINNATI, Jan. 06, 2026 (GLOBE NEWSWIRE) - Enable Injections, Inc. (“Enable”) a healthcare innovation company developing and manufacturing the enFuse ® On-Body Delivery System (OBDS), announced today that Sanofi is making a $30 million investment to accelerate Enable’s manufacturing build-out, strengthen its supply chain capabilities, and drive commercial growth. “This investment from one of our key partners shows support of the enFuse platform and our shared commitment to making large-volume subcutaneous injectable therapies more convenient for patients, including oncology,” said Michael D. Hooven, Chairman and CEO of Enable Injections. “Expanding our manufacturing capabilities is key to meeting the needs of our partners while bringing innovative treatment options to patients, worldwide.” This funding will further strengthen Enable’s ability to meet growing demand for the enFuse system, which is designed to subcutaneously administer large-volume medicines beginning with the click